SILO PHARMA INC (SILO) Fundamental Analysis & Valuation
NASDAQ:SILO • US82711P2011
Current stock price
0.3456 USD
+0 (+0.49%)
At close:
0.376 USD
+0.03 (+8.8%)
After Hours:
This SILO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SILO Profitability Analysis
1.1 Basic Checks
- In the past year SILO has reported negative net income.
- SILO had a negative operating cash flow in the past year.
- SILO had negative earnings in 4 of the past 5 years.
- SILO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- SILO has a Return On Assets of -79.51%. This is in the lower half of the industry: SILO underperforms 68.47% of its industry peers.
- The Return On Equity of SILO (-101.36%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.51% | ||
| ROE | -101.36% | ||
| ROIC | N/A |
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SILO has a better Gross Margin (65.42%) than 78.72% of its industry peers.
- SILO's Gross Margin has improved in the last couple of years.
- The Profit Margin and Operating Margin are not available for SILO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
2. SILO Health Analysis
2.1 Basic Checks
- SILO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SILO has more shares outstanding
- SILO has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- SILO has an Altman-Z score of -3.78. This is a bad value and indicates that SILO is not financially healthy and even has some risk of bankruptcy.
- SILO has a Altman-Z score (-3.78) which is comparable to the rest of the industry.
- There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.78 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
- SILO has a Current Ratio of 8.70. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.
- SILO has a Current ratio of 8.70. This is in the better half of the industry: SILO outperforms 74.47% of its industry peers.
- SILO has a Quick Ratio of 8.70. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.
- SILO has a Quick ratio of 8.70. This is in the better half of the industry: SILO outperforms 74.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.7 | ||
| Quick Ratio | 8.7 |
3. SILO Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 21.56% over the past year.
- Looking at the last year, SILO shows a decrease in Revenue. The Revenue has decreased by 0.00% in the last year.
- The Revenue has been growing by 12.51% on average over the past years. This is quite good.
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%
3.2 Future
- The Earnings Per Share is expected to decrease by -21.62% on average over the next years. This is quite bad
- SILO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by 0.00% yearly.
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. SILO Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SILO. In the last year negative earnings were reported.
- Also next year SILO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SILO's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
5. SILO Dividend Analysis
5.1 Amount
- No dividends for SILO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SILO Fundamentals: All Metrics, Ratios and Statistics
0.3456
+0 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2026-03-26/amc
Earnings (Next)05-07 2026-05-07
Inst Owners9.11%
Inst Owner Change0%
Ins Owners1.67%
Ins Owner Change8.56%
Market Cap4.60M
Revenue(TTM)72.00K
Net Income(TTM)-5.08M
Analysts82.86
Price TargetN/A
Short Float %2.44%
Short Ratio0.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 63.94 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.92 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.01
BVpS0.38
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.51% | ||
| ROE | -101.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.42% | ||
| FCFM | N/A |
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.7 | ||
| Quick Ratio | 8.7 | ||
| Altman-Z | -3.78 |
F-Score4
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
EBIT growth 1Y-30.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.95%
OCF growth 3YN/A
OCF growth 5YN/A
SILO PHARMA INC / SILO Fundamental Analysis FAQ
What is the fundamental rating for SILO stock?
ChartMill assigns a fundamental rating of 3 / 10 to SILO.
What is the valuation status of SILO PHARMA INC (SILO) stock?
ChartMill assigns a valuation rating of 0 / 10 to SILO PHARMA INC (SILO). This can be considered as Overvalued.
What is the profitability of SILO stock?
SILO PHARMA INC (SILO) has a profitability rating of 1 / 10.
What is the financial health of SILO PHARMA INC (SILO) stock?
The financial health rating of SILO PHARMA INC (SILO) is 7 / 10.